ASweetLife Team, Author at ASweetLife

JDRF and Eli Lilly to Fund Regenerative Medicine Research for Type 1 Diabetes

JDRF and Eli Lilly signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate the insulin-producing cells destroyed by the disease. The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body. This research is an example of regenerative medicine...

Positive Results for New Sanofi-aventis Type 2 Diabetes Drug

Sanofi-aventis announced that the GetGoal-X Phase 3 study of lixisenatide, a once-daily GLP-1 receptor agonist, has achieved primary efficacy endpoint. Lixisenatide, a glucagon-like peptide-1 agonist (GLP-1), is in development for the treatment of patients with type 2 diabetes mellitus.

USDA Recommends Eating More Fruit, Vegetables, Protein and Less Salt and Refined Grains

The US Department of Agriculture announced the release of the 2010 Dietary Guidelines for Americans, the federal government's evidence-based nutritional guidance to promote health, reduce the risk of chronic diseases, and reduce the prevalence of overweight and obesity through improved nutrition and physical activity....

Artificial Pancreas May Drastically Reduce Complications in Type 1 Diabetes Pregnancy

New research, funded by Diabetes UK, has found that use of an artificial pancreas by woman suffering from type 1 diabetes during pregnancy may drastically reduce cases of stillbirth and mortality rates...

Destroying Glucagon Receptors May Cure Diabetes

New findings by researchers at UT Southwestern Medical Center may hold a cure for type 1 diabetes. According to the findings, type 1 diabetes could be converted to an asymptomatic, non-insulin-dependent disorder by eliminating the actions of a specific hormone...

Novo Nordisk’s New Insulin Pen for Children Wins GOOD DESIGN Award

The Chicago Athenaeum Museum of Architecture and Design in cooperation with The European Centre for Architecture, Art, Design and Urban Studies have chosen to award Novo Nordisk a 2010 GOOD DESIGN™ Awardfor the NovoPen Echo, a new insulin pen designed specifically with the needs of children in mind...

Novo Nordisk Intends to Appeal Adverse Ruling in Prandin (repaglinide) Patent Case

Novo Nordisk announced it would appeal the US District Court for the Eastern District of Michigan's ruling regarding Novo Nordisk's US patent covering combination drugs Prandin and PrandiMet. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable...

FDA Rejects Afrezza, Mannkind’s Inhaled Insulin

The FDA's Center for Drug Evaluation and Research has issued a complete response letter to Mannkind corp. regarding the New Drug Application (NDA) for Afrezza (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with type 1 and type 2 diabetes...

Generic Version of Bayer’s Type 2 Diabetes Drug Precose Approved by FDA

The FDA has given final approval to Mylan Pharmaceuticals Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg. Acarbose is the generic version of Bayer's Precose tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes...

Novo Nordisk Launches Online Diabetes Support Program

Novo Nordisk launched Cornerstones4Care™, a comprehensive, highly customizable online support program for people living with diabetes. The program aims to be a one-stop source to learn about diabetes and innovative Novo Nordisk treatment options and delivery device systems. People can also receive recipes, look up food nutritional values, connect with others...